- Enzolytics ( OTCPK:ENZC ) will work with Abveris, a division of Twist Bioscience ( NASDAQ: TWST ), on the discovery of monoclonal antibodies against several viruses .
- The initial focus is on antibodies targeting SARS-CoV-2.
- Terms call for Abveris (also known as Twist Boston) to use human patient donor peripheral blood mononuclear cell samples and peptide screening tools provided by Enzolytics ( OTCPK:ENZC ) to perform rapid B cell screening and identify antigen-binding antibodies for further characterization by Enzolytics ( OTCPK:ENZC ).
- Abveris' expertise is in utilizing advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide gene-to-antibody discovery services.
- Enzolytics' ( OTCPK:ENZC ) artificial intelligence platform is used to identify highly conserved, immutable target sites on viruses, including HIV-1, feline leukemia virus, and feline immunodeficiency virus.
- A federal judge recently dismissed a lawsuit filed by one of Enzolytics' ( OTCPK:ENZC ) shareholders requiring the company to replace 10M shares allegedly stolen by third parties.
For further details see:
Twist Biosciences collaborates with Enzolytics on monoclonal antibodies for viruses